Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

作者：For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), Pierre D. Delmas, Robert R. Recker, C. H. Chesnut, Arne Skag, J. A. Stakkestad, Ronald Emkey, Jennifer Gilbride, Ralph C. Schimmer, Claus Christiansen · 发表于：Osteoporosis International · 年份：2004 · DOI：10.1007/s00198-004-1602-9 · 被引用次数：280 · 研究领域：Bone health and osteoporosis research、Bone health and treatments、Bone Metabolism and Diseases